Seres Therapeutics, Inc.MCRBNASDAQ
Loading
EV to Sales: Premium ValuationElevated
Percentile Rank100
5Y CAGR+30.5%
Studio
Year-over-Year Change

Enterprise value to sales ratio

5Y CAGR
+30.5%/yr
Long-term compound
Percentile
P100
Near historical high
vs 5Y Ago
3.8x
Strong expansion
Streak
1 yr
Consecutive growthElevated
PeriodValueYoY Change
2025214.22-
20240.00-
20230.00-
20220.00-100.0%
20214.37-92.3%
202056.59+1015.1%
20195.07+35.8%
20183.74-68.7%
201711.93-25.9%
201616.11-